We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Biocept, Inc., a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces that it has entered into laboratory ...
Biocept has entered into a clinical study agreement with the University of Texas Southwestern Medical Center.the study is designed to evaluate the clinical utility of Biocept's Target Selector platform for patients diagnosed with ALK-positive non-small ce